Lode Debrabandere - Osiris Therapeutics President CEO, Director
CEO
Dr. Lode Debrabandere Ph.D. is President Chief Executive Officer Director of Osiris Therapeutics Inc. Prior to joining Osiris Dr. Debrabandere served for over four years with BristolMyers Squibb as Vice President for Strategic Marketing for Neuroscience and Infectious Diseases. He joined us in July 2006 as our Vice President and General Manager of Therapeutics. He became our Chief Operating Officer in October 2012 and was elected to our Board of Directors in January 2014 since 2014.
| Age | 49 |
| Tenure | 10 years |
| Phone | 443 545-1800 |
| Web | www.osiris.com |
Osiris Therapeutics Management Efficiency
Osiris Therapeutics' management efficiency ratios could be used to measure how well Osiris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 6.74 M in liabilities with Debt to Equity (D/E) ratio of 0.7, which is about average as compared to similar companies. Osiris Therapeutics has a current ratio of 3.34, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Osiris Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Osiris Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Osiris Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Osiris to invest in growth at high rates of return. When we think about Osiris Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 5 records | CEO Age | ||
| David Roberts | Verra Mobility Corp | 52 | |
| Frederick III | Saia Inc | 56 | |
| Richard ODell | Saia Inc | 56 | |
| Michael OLeary | Ryanair Holdings PLC | 63 | |
| Mark Stone | Verra Mobility Corp | 52 | |
Management Performance
| Return On Equity | -3.0E-4 | |||
| Return On Asset | -2.0E-4 |
Osiris Therapeutics Leadership Team
Elected by the shareholders, the Osiris Therapeutics' board of directors comprises two types of representatives: Osiris Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Osiris. The board's role is to monitor Osiris Therapeutics' management team and ensure that shareholders' interests are well served. Osiris Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Osiris Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Brandt, Independent Director | ||
| Jason Keefer, Interim President CEO, Vice President of Marketing | ||
| David White, Independent Director | ||
| Joel Rogers, Interim CFO | ||
| Gregory Law, CFO | ||
| Charles Reinhart, Director | ||
| Aziz Ahmad, IR Contact | ||
| Uwe Sommer, Independent Director | ||
| Dwayne Montgomery, Interim CEO and Chief Bus. Officer | ||
| Alberto Avendano, Chief Medical Officer | ||
| HansGeorg Klingemann, Independent Director | ||
| David Dresner, Interim President and CEO | ||
| Peter Friedli, Co-Founder and Chairman | ||
| Lode Debrabandere, President CEO, Director | ||
| Linda Palczuk, President CEO | ||
| Jonathan Hopper, Chief Medical Officer | ||
| Adrian Mollo, General Counsel | ||
| Samson Tom, President CEO | ||
| Linda Chang, CFO | ||
| Frank Czworka, COO | ||
| Thomas Knapp, Independent Director | ||
| Willi Miesch, Independent Director | ||
| Jay Moyes, Independent Director | ||
| Alla Danilkovitch, Vice President - Research & Development |
Osiris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Osiris Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.0E-4 | |||
| Return On Asset | -2.0E-4 | |||
| Profit Margin | (0.0004) % | |||
| Operating Margin | 6.62 % | |||
| Current Valuation | 621.32 M | |||
| Shares Outstanding | 34.53 M | |||
| Shares Owned By Insiders | 52.20 % | |||
| Shares Owned By Institutions | 25.24 % | |||
| Number Of Shares Shorted | 165.38 K | |||
| Price To Earning | 17.76 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Osiris Stock
If you are still planning to invest in Osiris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Osiris Therapeutics' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |